
Stephan Rosenkranz
Univ. of Cologne, Germany
P1-1. Importance of RV adaptation and function in pressure- versus volume-loaded right heart
CV
Samuel G. Rayner
Univ. of Washington, USA
P2-1. Beyond the Numbers: Diagnostic Precision and Biological Endotypes in Pulmonary Arterial Hypertension
CV
Takahiro Hiraide
Keio Univ. School of Medicine, Japan
P2-3. PAH with cardiopulmonary comorbidities: Importance of patient-specific treatment goal
CV
Stephan Rosenkranz
Univ. of Cologne, Germany
P2-4. The changing treatment paradigm in pulmonary hypertension
CV
John Feenstra
Pulmonary Hypertension Research Queensland, Australia
P3-1. Pragmatic Strategies for Overcoming Barriers to Pulmonary Hypertension Care: An Asia-Pacific Perspective
CV
Takahiro Hiraide
Keio Univ. School of Medicine, Japan
P3-2. RNF213 R4810K: Asian-specific poor prognostic factor and its underlying mechanism
CV
Chih-Hsin Hsu
National Cheng Kung Univ., Taiwan
P3-3. Challenges and Opportunities for Non-PAH PH
CV
Ju-Hee Lee
Chungbuk National Univ., Korea
P3-4. The Guideline–Reality Gap: PAH Treatment Hurdles in Korea
CV
Young Seok Cho
Sungkyunkwan Univ., Korea
P5-2. Nuclear medicine for the diagnosis and treatment response evaluation of pulmonary hypertension
CV
Ran Heo
Hanyang Univ., Korea
P6-1. Echo-based Screening and Probability Assessment in Pulmonary Hypertension
CV
Jino Park
Inje Univ., Korea
P6-2. Integration of Echo and RHC: Bridging the Gap in Clinical Practice
CV
Jae-Hyeong Park
Chungnam National Univ., Korea
P6-3. Right heart function and Right Ventricular–Pulmonary Arterial Coupling in Pulmonary Hypertension

Seonhwa Lee
Yonsei Univ., Korea
P6-4. Exercise induced PH: Clinical Significance and Diagnostic Pitfalls
CV
Hiromi Matsubara
NHO Okayama Medical Center, Japan
P7-1. Treprostinil Palmitil Inhalation Powder as a Treatment for PAH
CV
John Feenstra
Pulmonary Hypertension Research Queensland, Australia
P7-2. Defining Disease Modification in PAH: Do Emerging Therapies Deliver?
CV
Derek Solum
United Therapeutics, USA
P7-3. Ralinepag for the treatment of pulmonary arterial hypertension: results of the ADVANCE Outcomes study
CV
Hiromi Matsubara
NHO Okayama Medical Center, Japan
P10-1. Why we need 'RHJ'? From EASOPH's perspectives
CV
Chih-Hsin Hsu
National Cheng Kung Univ., Taiwan
P10-3. How do we develop 'RHJ' to the top soon? From EASOPH's perspectives
CV
Samuel G. Rayner
Univ. of Washington, USA
P10-4. How do we Deliver RHJ to the Top? A Global Perspective
CV
Macalester College, B.A., Biology (cum laude), 2006
University of Minnesota Medical School, M.D., 2011
Residency: Internal Medicine, University of Washington, 2011–2014
Fellowship: Pulmonary, Critical Care & Sleep Medicine, University of Washington, 2015–2018
Assistant Professor of Medicine, Division of Pulmonary, Critical Care & Sleep Medicine, University of Washington. Principal Investigator of an NIH-funded pulmonary vascular biology laboratory. Medical Director of the UW Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Program and Associate Director of the UW Hereditary Hemorrhagic Telangiectasia (HHT) Center.
In vitro modeling of pulmonary arterial hypertension using bioengineered vascular platforms
Hemodynamic forces and pulmonary endothelial dysfunction
Translational multi-omics in pulmonary arterial hypertension
Diagnosis and management of chronic thromboembolic pulmonary hypertension
Author of 44 peer-reviewed publications spanning pulmonary vascular disease, vascular biology, and related fields. Selected highlights:
Rayner SG et al. Multiphoton-guided Creation of Complex Organ-specific Microvasculature. Adv Healthc Mater. 2021.
Rayner SG et al. Zone of Uncertainty in Pulmonary Arterial Wedge Pressure Measurement. Am J Respir Crit Care Med. 2024.
Hirsch K*, Mandrycky CJ*, Kwan I, …Rayner SG. Endothelial Responses to Shear Stress and Pressure in PAH. bioRxiv. 2025 (under review).
Apr 1982- Mar 1988 MD; Okayama University Medical School
May 1988- Apr 1990 National Okayama Hospital, Department of Internal Medicine, Residency
May 1990- Apr 1993 National Cardiovascular Center, Department of Cardiology, Residency
Sep 2000 PhD; Okayama University Graduate School of Medicine and Dentistry
Okayama University Graduate School of Medicine and Dentistry, Department of Cardiology; Associate Professor (May 2000- Apr 2003)
National Hospital Organization, Okayama Medical Center, Department of Cardiology; Director (May 2003- Mar 2020, Department of Clinical Science; Director (May 2010- Mar 2019)
Entire Medical Departments; Director (Apr 2019 - Mar 2021), Vice President (Apr 2021 – active)
clinical and physiological aspects of pulmonary hypertension
diagnosis and treatment of Group I PH
Interventional treatment of Group IV PH
J Heart Lung Transplant. 2025. doi: 10.1016/j.healun.2025.10.031
Lancet Respir Med. 2025. doi: 10.1016/S2213-2600(25)00127-4
Circ Cardiovasc Interv. 2025. doi: 10.1161/CIRCINTERVENTIONS.125.016172
J Am Coll Cardiol. 2025;85:2270-2284. doi: 10.1016/j.jacc.2025.04.021
Clin Nucl Med. 2025;50:623-630. doi: 10.1097/RLU.0000000000005919
Medical Graduate 2006 – 2012 Doctor of Medicine Keio University School of Medicine, Tokyo, JAPAN
Doctoral Course 2017 – 2020 Doctor of Philosophy Keio University School of Medicine, Tokyo, JAPAN
Residency 2012 - 2014 Internal Medicine Keio University Hospital, Tokyo, JAPAN
Fellowship 2014 - 2017 Cardiology Yokohama Citizen’s Municipal Hospital Kanagawa, JAPAN
Research Fellowship 2017 - 2020 Cardiology Keio University School of Medicine, Tokyo, JAPAN
Postdoctoral Fellowship 2021 – Present Cardiology Keio University School of Medicine, Tokyo, JAPAN
Fellowship 2025 – Present Medical genomics National Cerebral and Cardiovascular Center, Osaka, JAPAN
I have focused on understanding the molecular mechanisms of pulmonary hypertension, right ventricular dysfunction, cardiac hypertrophy, and vascular diseases. I have conducted extensive basic researches on developing new therapies for the treatment of pulmonary arterial hypertension (PAH) using gene-editing technologies. My current role as a clinical physician at Keio University Hospital allows me to combine clinical practice with my research endeavors.
My researches have been recognized with several awards, including the “Best Young Investigator’s Award” and “Outstanding Research Award” from the Japan Cardiovascular Society, the “Young Researcher Award” from the European Society of Cardiology Pulmonary Circulation and Right Ventricular Function Working Group, the “Moderated Poster Presentation Winner” from the European Society of Cardiology, the “Oral Presentation Award” at the 1st Asian Cardiovascular Symposium at Basic Cardiovascular Sciences held in the USA, and the “Best Young Investigator’s Award” at the Japanese Pulmonary Circulation and Pulmonary Hypertension Society Conference.
Hiraide T, Tsuda N, Momoi M, et al. CXCL12/CXCR4 pathway as a novel therapeutic target for RNF213-associated pulmonary arterial hypertension. Sci Rep. 2024;14:26604.
Hiraide T, Suzuki H, Momoi M, et al. RNF213-associated vascular disease: a concept unifying various vasculopathies. Life. 2022;12:555.
Hiraide T, Kataoka M, Suzuki H, et al. Poor outcomes in carriers of the RNF213 variant (p.Arg4810Lys) with pulmonary arterial hypertension. J Heart Lung Transplant. 2020;39:103–112.
Hiraide T, Kataoka M, Suzuki H, Aimi Y, Chiba T, Kanekura K, Satoh T, Fukuda K, Gamou S, Kosaki K. SOX17 mutations in Japanese patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2018;198:1231–1233.
Hiraide T, Teratani T, Uemura S, et al. Pulmonary arterial hypertension caused by AhR signal activation protecting against colitis. Am J Respir Crit Care Med. 2021;203:385–388.
MBBS, University of Queensland, 1996
BMedSc (with Distinction), Physiology and Pharmacology, University of Queensland, 1995
FRACP, Royal Australasian College of Physicians, 2005
Transplant and Pulmonary Hypertension Fellowship, The Prince Charles Hospital, 2005
Thoracic and Sleep Disorders Physician; Pulmonary Hypertension Specialist, 2005-Present
Lead Physician, Pulmonary Vascular Disease Unit/QLTS, The Prince Charles Hospital, 2015-Present
Director, Wesley Pulmonary Hypertension Unit, Wesley Hospital, 2008-Present
Director, Pulmonary Hypertension Research Queensland, 2025-present
President, Pulmonary Hypertension Society of Australia and New Zealand (PHSANZ), 2021-Present
Senior Lecturer in Medicine, University of Queensland, 2006–Present
Phase 1 to 4 Clinical Trials
Clinical trials in Groups 1 to 4
Exercise in PHT and exercise MRI
Kearney K et al. (incl. Feenstra J). Impact of left heart disease risk factors on outcomes in PAH therapy. Chest. 2024;165(4):967–977.
Feenstra J et al. Effectiveness of epoprostenol in PAH: findings of an Australian retrospective chart review. Intern Med J. 2020;50(11):1377–1384.
Anderson J et al. (incl. Feenstra J). Retrospective Validation of the REVEAL 2.0 Risk Score with the ANZ PH Registry. Chest. 2020;157(1):162–172.
Scalia GM et al. (incl. Feenstra J). ePLAR – echocardiographic pulmonary to left atrial ratio: a novel parameter to differentiate pre- and post-capillary PH. Int J Cardiol. 2016;212:379–386.
H-index: 10. ORCID: 0009-0006-2840-9272. Full publication list available on request.
Ph.D. in Medicine 2021 Graduate School, Chungbuk National University
M.S. in Medicine 2010 Graduate School, Chungbuk National University
M.D. 2006 College of Medicine, Chungbuk National University
Korean Society of Pulmonary Hypertension Member; Councilor; International Director
Korean Society of Cardiology Member
Korean Society of Heart Failure Member; Councilor; Director of External Affairs
Korean Society of Echocardiography Member; Councilor; Planning Committee; Ethics Committee
Korean Society of Hypertension Member; Scientific Committee; Policy Committee
Korean Vascular Society (KOVAS) Member; Chair, Healthcare Big Data Committee
Korean Association of Internal Medicine Member
Assistant Professor Mar 2024 – Mar 2025 Department of Internal Medicine, College of Medicine, Chungbuk National University
Director, Division of Healthcare Artificial Intelligence May 2021 – Feb 2024
Department of Precision Medicine, Korea National Institute of Health
Clinical Professor Mar 2013 – Feb 2024 Division of Cardiology, Chungbuk National University Hospital
Clinical Fellow Mar 2011 – Feb 2013 Division of Cardiology, Seoul National University Hospital
Resident Mar 2007 – Feb 2011 Department of Internal Medicine, Chungbuk National University Hospital
Intern Mar 2006 – Feb 2007 Chungbuk National University Hospital
She was a Vice-President of Japanese Pulmonary Circulation and Pulmonary Hypertension Society (JPCPHS) during 2015-2021. She graduated from Nagasaki University School of Medicine and obtained her Ph.D. from Osaka University Graduate School of Medicine.
From 1987, she worked at The Center for Cardiovascular Research, The Toronto Hospital, and since 1990, conducted research on signal transduction of cytokines and growth factors in cardiac myocytes at the Department of Cardiology, Osaka University Graduate School of Medicine.
She was appointed as Vice-President of Osaka University in 2014, and also worked as a Trustee of National Cerebral and Cardiovascular Center (2018-2024) and an Auditor of National Institute for Quantum Science and Technology, Japan (2020-2024).
Although she has a longstanding interest in genetics and biological mechanisms of the development of cardiomyopathy, her research interests include pulmonary circulation and cardiopulmonary interrelations from the viewpoints of genetics and inflammation
Over 100 reviewed basic and clinical research papers;
Successful treatment of severe combined post- and pre-capillary pulmonary hypertension in a patient with idiopathic restrictive cardiomyopathy. Pulm Circ. 2018 Jul-Sep;8(3)
Interleukin-6/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension. Proc Natl Acad Sci U S A. 2015 May 19;112(20):E2677-86. doi: 10.1073/pnas.1424774112.
The challenge of the "estrogen paradox" in pulmonary arterial hypertension. Circ J. 2013;77(8):1992-3.
Pulmonary arterial hypertension associated with chronic active Epstein-Barr virus infection. Intern Med. 2011;50(2):119-24.
1979/07 MD. NATIONAL DEFENSE MEDICAL UNIVERSITY
1995/07-1997/07 -Post-doctoral fellowship, Hospital of the University of Pennsylvania, USA
2015/02 & /06 -Master class of Pulmonary Vascular Disease, Bologna University Hospital, Bologna, Italy
2018/12- Director, Center for PH and PVD, CMUH, Taichung, Taiwan
2015/04-2027/04 -Chairperson, Taiwan Pulmonary Hypertension Association (TPHA)
Pulmonary hypertension including clinical and genetic studies
Pulmonary hypertension publication in recent 5 years
Liang K-W, Chang S-K, Chen Y-W, Tsai W-J, Wang K-Y*(corresponding author). A cluster of heritable pulmonary arterial hypertension cases in a family with all three siblings carrying the same novel AQP1 c.273C>G variant-a case report. Pulm Circ. 2023;e12211. https: //doi.org/10.1002/pul2.12211
I Hsin Tai, Tsung-Cheng Shyu, Kai-Sheng Hsieh, Ke-Wei Chen, Wan-Jane Tsai, Kuo-Yang Wang*(corresponding author). Case report: The impact of percutaneous atrial septal defect closure in pulmonary hypertension with co-existing cor triatriatum sinister and multiple cardiac comorbidities. Front. Cardiovasc. Med., 07 September 2022 Sec. Cardiovascular Therapeutics https://doi.org/10.3389/fcvm.2022.913391
Kae-Woei Liang, Sheng-Kai Chang, Yu-Wei Chen, Wei-Wen Lin, Kuo-Yang Wang*(corresponding author). Whole exome sequencing of patients with primary pulmonary arterial hypertension in central Taiwan. Front Cardiovasc Med. 22 June 2022, doi: 10.3389/fcvm.2022.911649
Liang KW, Wei HJ, Wang KY*(corresponding author). Sustained hemodynamic and clinical improvements for a patient with idiopathic pulmonary arterial hypertension over 1.5 years after balloon atrial septostomy: a case report. Front Cardiovasc Med. 2022 Apr 7;9:868123. doi:10.3389/fcvm.2022.868123. eCollection 2022
1993년 3월 ~ 1999년 2월 고려대학교 의과대학 의학사
2002년 3월 ~ 2004년 2월 고려대학교 의과대학 대학원 의학 석사 (내과학)
2004년 3월 ~ 2007년 2월 고려대학교 의과대학 대학원 의학 박사 (순환기내과)
1999년 3월 ~ 2000년 2월 고려대학교 병원 수련의
2000년 3월 ~ 2004년 2월 고려대학교 병원 내과 전공의
2004년 3월 ~ 2007년 2월 고려대학교 병원 순환기 내과 전임의/임상강사
2007년 5월 ~ 2009년 4월 Brigham and Women’s Hospital Research Fellow
2009년 5월 ~ 2010년 2월 인하대학교 병원 심장내과 임상강사
2010년 3월 ~ 2014년 2월 인하대학교 병원 심장내과 조교수
2014년 3월 ~ 2019년 2월 인하대학교 병원 심장내과 부교수
2018년 ~ 2019년 Brigham and Women’s Hospital Visiting Associate Professor
2019년 3월 ~ 현재 인하대학교 병원 심장내과 교수
대한내과학회 현) 윤리위원
대한심장학회 현) 편집위원, 정책위원
한국심초음파학회 현) 홍보이사
대한심부전학회 현) 국제교류이사
대한고혈압학회 현) 홍보위원
Professor Aldalaan earned his medical degree from King Saud University. He completed residencies in internal medicine at King Faisal Specialist Hospital & Research Centre and Duke University Medical Center. He then completed a pulmonary and critical care fellowship at the University of Virginia.
Abdullah Moshin Aldalaan, MBBS, is Director of the Pulmonary Hypertension Program of Excellence and a Consultant Pulmonologist at the King Faisal Specialist Hospital & Research Centre in Riyadh, Saudi Arabia. He also serves as a Professor in the College of Medicine at Alfaisal University, also located in Riyadh. In addition to his current role as President of the Saudi Association for Pulmonary Hypertension, Dr. Aldalaan has held leadership positions in numerous professional societies focused on respiratory disease and has lectured nationally and internationally.
Dr. Aldalaan established the lung transplant program at King Faisal Specialist Hospital & Research Centre in 2003. He also established the institution’s pulmonary hypertension (PH) treatment program, which is the only program in the area providing comprehensive diagnostic and therapeutic protocols for patients with PH. The program offers all available internationally recognized medical interventions for PH and has become a region-wide reference center for pulmonary hypertension education and treatment.
Dr. Aldalaan also is an active clinical trialist and has published more than 50 papers in peer-reviewed journals.
Recent publication of note:
Aldalaan A, Saleemi SA, Weheba I, et al. Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT). Pulm Circ. 2022;12:e12083, doi: 10.1002/pul2.12083.
Apr 1982- Mar 1988 MD; Okayama University Medical School
May 1988- Apr 1990 National Okayama Hospital, Department of Internal Medicine, Residency
May 1990- Apr 1993 National Cardiovascular Center, Department of Cardiology, Residency
Sep 2000 PhD; Okayama University Graduate School of Medicine and Dentistry
Okayama University Graduate School of Medicine and Dentistry, Department of Cardiology; Associate Professor (May 2000- Apr 2003)
National Hospital Organization, Okayama Medical Center, Department of Cardiology; Director (May 2003- Mar 2020, Department of Clinical Science; Director (May 2010- Mar 2019), Entire Medical Departments; Director (Apr 2019 - Mar 2021), Vice President (Apr 2021 – active)
clinical and physiological aspects of pulmonary hypertension
diagnosis and treatment of Group I PH
Interventional treatment of Group IV PH
JACC Cardiovasc Interv. 2024;17:707-708. doi: 10.1016/j.jcin.2023.11.022
Eur Respir J. 2024. doi: 10.1183/13993003.01294-2024
Can J Cardiol. 2024. doi: 10.1016/j.cjca.2024.05.003
J Heart Lung Transplant. 2024. doi: 10.1016/j.healun.2024.05.007
Circulation. 2024. doi: 10.1161/CIRCULATIONAHA.124.068610
Professor Rosenkranz studied Medicine n Giessen and New York, and graduated from the Justus Liebig University in Giessen, Germany, before becoming a resident physician and research fellow at the University of Cologne, Germany. Following his doctoral degree, he undertook a post-doctoral fellowship at Harvard Medical School, USA, before returning to Cologne. He is board certified in Internal Medicine, Cardiology, and Intensive Care Medicine, and serves as an interventional cardiologist.
Prof. Rosenkranz is Full Professor of Cardiology (“Cardiopulmonary interaction”), currently holds the posts of Chair, Cologne Cardiovascular Research Center (CCRC) and Head of Expert Center on Pulmonary Hypertension, Univ. of Cologne; Germany; He is past-chair of the Working Group “Pulmonary Circulation and Right Ventricular Function” of the European Society of Cardiology (ESC), chair of the “Committee on Lung, Sleep & Pulmonary Hypertension” of the Heart Failure Association (HFA) of the ESC, and served as task force chair of the 2022 ESC/ERS guidelines for pulmonary hypertension.
Prof. Rosenkranz is interested in translational research focusing on metabolism, inflammation, and growth factor signaling in cardiovascular disease. He has conducted numerous clinical trials in the fields of heart failure and pulmonary hypertension (phase I, II, III, IV), contributing as Principal Investigator or Steering Committee member, and is Head ("Principal Investigator") of the working group on "Molecular Cardiology," with a research focus on Signal transduction and pathobiological relevance of tyrosine kinases in cardiovascular disease.
Prof. Rosenkranz has published >350 articles in peer-reviewed journals, and >45 book articles (Scopus H-index = 69; Google Scholar H-index = 80). He serves as Associate Editor for Eur J Heart Fail, Cardiovasc Res, Right Heart J, Curr Heart Fail Rep; and as a reviewer for numerous scientific journals, including J Am Med Assoc, Lancet, Circulation, Eur Heart J, Eur J Heart Fail, Eur Respir J.
Visiting Scholar , University of Chicago Medical Center
PhD, Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan
Master Degree, Pulmonary Vascular Disease, University of Bologna, Bologna, Italy
MD, China Medical College, Taichung, Taiwan
2022- Professor, National Cheng Kung University
2023-, Deputy Superintendent, National Cheng Kung University Hospital
2020-2023 Medical Secretory, National Cheng Kung University Hospital
2019-2020 Deputy Superintendent, National Cheng Kung University Hospital Dou-Liou Branch
2004 Attending Physician, National Cheng Kung University Hospital
Pulmonary Hypertension
Heart Failure
Heart Transplant Care
Critical Care
Post Resuscitation Care
1991.3 Graduate from Kyushu University School of Medicine
1993.6-1995.5 Research Fellow, Cardiovascular Medicine, Kyushu University
1998.10-2001.11 Research Fellow, Brigham and Women’s Hospital, Harvard Medical School
2011.8-2013.6 Associate Professor, Cardiovascular Medicine, Tohoku University
2013.7-Present Professor and Chairman, Cardiovascular Medicine, Kurume University
Yoshihiro Fukumoto is Professor and Chairman of Cardiovascular Medicine in Kurume University School of Medicine, who is also a Fellow of JCC, JCS, AHA, and ESC. Dr. Fukumoto was awarded his medical degree from Kyushu University School of Medicine, and followed this with a PhD in coronary arteriosclerosis in Kyushu University, Fukuoka, Japan. He is a president of Japanese Pulmonary Circulation and Pulmonary Hypertension Society (since April 2024), Japanese Association of Cardiac Rehabilitation (since August 2024).
General cardiology
Pulmonary circulation
Heart failure
atherosclerosis
Cardiac rehabilitation
Minatsuki S, Fukumoto Y, et al. Significance of diffusing capacity of the lungs for carbon monoxide on chronic thromboembolic pulmonary hypertension. Thorax. 2026:thorax-2025-223670.
Sugiyama Y, Fukumoto Y, et al. Utility of liver stiffness for the classification of portopulmonary hypertension in precapillary pulmonary hypertension. Int J Cardiol. 2025;429:133126.
Satoh T, Fukumoto Y, et al. Hypopituitarism Induced by Continuous Infusion of PGI2 Analogues: A Case Series and the Role of ACTH Screening and Hydrocortisone Treatment. Pulm Circ. 2025;15:e70116.
Yamashita J, Fukumoto Y, et al. Effects of pulmonary endarterectomy and balloon pulmonary angioplasty in older adults with chronic thromboembolic pulmonary hypertension: A sub-analysis of the CTEPH AC registry. Int J Cardiol Heart Vasc. 2025;60:101751.
Yamaji K, Fukumoto Y, et al. Catheter-based examination for pulmonary microcirculatory function in patients with pulmonary hypertension. PLoS One. 2024;19:e0312609.
Prof. Jing obtained his M.D. Ph.D. degree in 1998 from Peking Union Medical College, and then participated in 2-year postdoctoral clinical fellow training at the Hospital Antoine Béclère with Professors Gerald Simonneau and Marc Humbert, in Paris-Sud Université, France. He also received the training by World Heart Federation Emerging Leaders Programme and the American College of Cardiology Global Leadership Training program in 2014.
Prof. Jing is the Chairman of the Cardiovascular Medicine Department, Guangdong Cardiovascular Institute. He also is the associate Editor of HEART (the BMJ family journals), Senior Editor of JACC, the President of Guangdong Society of Cardiology. Prof. Jing led more than 100s International and National project / clinical trials on the genetics and basic / clinic research on pulmonary circulation and thrombosis, he is also the lead author on the National Clinical Guideline for Pulmonary Embolism and Pulmonary Hypertension organized by Chinese Society of Cardiology. He received almost all of most important National awards for Scientist-Physicians.
Cardiovascular Medicine
Congenital heart disease
Pulmonary Circulation
Clinical features and survival in Taksyasu's arteritis-associated pulmonary hypertension: a nationwide study. Eur Heart J. 2021;42(42):4298-4305.
Percutaneous Pulmonary Angioplasty for Patients With Takayasu Arteritis and Pulmonary Hypertension. J Am Coll Cardiol. 2022;79(15):1477-1488.
Prognostic Value of Plasma Immunoglobulin G N-Glycome Traits in Pulmonary Arterial Hypertension. J Am Coll Cardiol. 2024; 84(12):1092-1103.
Evaluation of recombinant human prourokinase for acute pulmonary embolism: A phase 2, randomized clinical trial. Med. 2026 Mar 30:101068.
sST2 and IL-6 predict prognosis of medically treated chronic thromboembolic pulmonary hypertension. Eur Respir J. 2026 Jan 22:2502367.
M.D., College of Medicine, Seoul National University, Seoul, Korea (2005)
M.S., Department of Medicine, Seoul National University Graduate School, Seoul, Korea (2013)
Ph.D., Department of Medicine, University of Ulsan Graduate School, Seoul, Korea (2018)
Residency & Clinical Fellowship, Dept. of Obstetrics and Gynecology (Maternal-Fetal Medicine), Seoul National University Hospital (2007–2013)
Residency & Clinical/Research Fellowship, Dept. of Pathology (Gynecologic, Pediatric & Placental Pathology), Asan Medical Center, University of Ulsan College of Medicine (2013–2020)
Postdoctoral Scholar, Dept. of Biomedical Engineering (Computational Biology), Oregon Health and Science University (2020–2022)
Clinical Assistant Professor, Dept. of Pathology, Seoul National University Hospital (2023–2026)
Clinical Associate Professor, Dept. of Pathology, Seoul National University Hospital (2026–present)
Pediatric pathology: rare disease diagnosis, molecular pathology, and digital atlas construction for pediatric tumors and genetic disorders
Cardiovascular pathology: CRP biology in abdominal aortic aneurysm and coronary artery bypass graft remodeling
Multiplexed tissue imaging and spatial transcriptomics for digital pathology
Placental pathology: pathophysiology of MPFD, preeclampsia, and chronic inflammatory placental disorders
55 peer-reviewed publications (SCI/SCIE); recent highlights include:
Multiplexed imaging-driven single-cell analysis of abdominal aortic aneurysm by CRP deposition (Translational Research, 2025, 1st author)
Plasma proteome profiling of MPFD in recurrent miscarriage (Placenta, 2025, 1st author)
Spatial whole-transcriptomic analysis of CRP in abdominal aortic aneurysm (Frontiers in Immunology, 2024, 1st author)
Dual-modality multiplexed imaging for whole-slide digital pathology (Cell Reports Methods, 2023, 1st author) 2 book chapters; 13 patents (placental diagnostics, cardiovascular imaging, digital pathology AI)
2015-2019: Graduate School (Ph.D.), Department of Medicine, College of Medicine, Yonsei University
2001-2007: College of Medicine, Inje University
2023.3- : Associate professor, College of Medicine, Hanyang University
2019-2023: Assistant professor , College of Medicine, Hanyang University
2016-18: Clinical lecturer, Asan medical center
2012-15: Clinical Fellowship, Severance Hospital
2007-2012 : Internship & Residentship, Sanggye Paik Hospital
Coronary artery disease
Valvular heart disease
Heart failure
Pulmonary hypertension
Lee SE, Chang HJ, Sung JM, Park HB, Heo R, Rizvi A, Lin FY, Kumar A, Hadamitzky M, Kim YJ, Conte E, Andreini D, Pontone G, Budoff MJ, Gottlieb I, Lee BK, Chun EJ, Cademartiri F, Maffei E, Marques H, Leipsic JA, Shin S, Choi JH, Chinnaiyan K, Raff G, Virmani R, Samady H, Stone PH, Berman DS, Narula J, Shaw LJ, Bax JJ, Min JK. Effects of Statins on Coronary Atherosclerotic Plaques: The PARADIGM Study. JACC Cardiovasc Imaging. 2018 Oct;11(10):1475-1484. doi: 10.1016/j.jcmg.2018.04.015. Epub 2018 Jun 13. PMID: 29909109.
Kim DH, Heo R, Handschumacher MD, Lee S, Choi YS, Kim KR, Shin Y, Park HK, Bischoff J, Aikawa E, Song JM, Kang DH, Levine RA, Song JK. Mitral Valve Adaptation to Isolated Annular Dilation: Insights Into the Mechanism of Atrial Functional Mitral Regurgitation. JACC Cardiovasc Imaging. 2019 Apr;12(4):665-677. doi: 10.1016/j.jcmg.2017.09.013. Epub 2017 Dec 13. PMID: 29248661; PMCID: PMC5993562.
2005.3 – 2011.2, M.D. & Bachelor of Medicine, College of Medicine, Chosun University, Gwangju, Korea
2014.3 – 2016.2, Master of Medicine, Graduate School of Ulsan University, Seoul, Korea
2021.3 – 2025.2, Ph.D. in Medicine, Graduate School of Ulsan University, Seoul, Korea
2012.3 – 2016.3 Residency in Internal Medicine, Asan Medical Center, Seoul, Korea
2019.5 – 2021.2 Cardiology Fellowship, Inje University, Haeundae Paik Hospital, Busan, Korea
2021.3 – 2022.2 Cardiology Fellowship, Asan Medical Center, Seoul, Korea
2022.3 – 2026.3 Assistant Professor, Inje University, Haeundae Paik Hospital, Busan, Korea
2026.4 – present Associate Professor, Inje University, Haeundae Paik Hospital, Busan, Korea
Cardiac imaging
Advanced heart failure and cardiomyopathy
Critical care cardiology
Cardiovascular genetics
Pulmonary hypertension
Park J. et al. Bovine pericardial versus porcine bioprosthetic mitral valves: results from a Korean Nationwide Cohort Study. Eur J Cardiothorac Surg. 2023 Jun 1;63(6):ezad165.
Park J. et al. Spontaneous Resolution of Extensive Iatrogenic Type A Aortic Dissection After Transcatheter Aortic Valve Replacement. JACC Case Rep. 2022 Apr 20;4(8):464-469.
Park J, Nam SH, et al. Long‑term outcomes and prognostic factors after aortic valve surgery in patients with Takayasu arteritis Gen Thorac Cardiovasc Surg. 2022 Nov 22.
Park J, et al. Safety concern with electrical cardioversion of persistent atrial fibrillation with slow ventricular response. Pacing Clin Electrophysiol. 2022 Aug;45(8):963-967.
Park J, Kim JH, Jeong YJ, et al. Different Clinical Features between Definite and Possible Takotsubo Syndrome in a Tertiary Referral Hospital. Cardiology. 2022;147(2):154-164.
College: Harvard University, 1989, A.B. (Magna Cum Laude, Biology)
Medical School: University of Chicago Pritzker School of Medicine, 1994, M.D.
Internship: University of Chicago, Internal Medicine, 1994-1995, 1996-1998
Residency: University of California San Francisco, Anesthesiology, 1995-1996
Fellowship: University of California San Diego, Pulmonary and Critical Care Medicine, 1998-2001
Faculty at UCSD since 2001. Fellowship program director 2009-2017. Currently, Professor of Medicine in the Division of Pulmonary, Critical Care, Sleep Medicine, & Physiology. Section Chief of Pulmonary Vascular Medicine. Medical Director of Pulmonary Thromboendarterectomy Program.
Evaluation and treatment of pulmonary arterial hypertension
Interventional and medical management of chronic thromboembolic disease
Perioperative management following pulmonary thromboendarterectomy
Balloon pulmonary angioplasty for chronic thromboembolic disease
Clinical trials in pulmonary hypertension
As of Nov 2025: 132 peer-reviewed publications on pulmonary hypertension including, pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Lead author for the 5th, 6th, and 7th World Symposium on Pulmonary Hypertension task force on “Chronic Thromboembolic Pulmonary Hypertension”. 4th World Symposium on Pulmonary Hypertension task force member: “Endpoints and Clinical Trial Design in PAH” and “Interventional and Surgical Modalities of Treatment in PH”.
1976 – 1978 Premedical Course, Tokyo Medical and Dental University, Chiba, Japan
1978 – 1982 M.D., Tokyo Medical and Dental University, Tokyo, Japan
2000 Ph.D. (Doctor of Medicine), Tokyo Medical and Dental University, Tokyo, Japan
1991 Board certified in Pediatrics, Japanese Pediatric Society
2011 Board certified in Pediatric Cardiologist, Japanese Society of Pediatric Cardiology and Cardiac Surgery
2011 Board certified in PALS provider, American Heart Association
Japanese Medical Specialty Board and Instructor of Pediatrics
Specialty Board of Pediatric Cardiology
Honorary fellow of Japanese Society of Pediatric Cardiology and Cardiac Surgery
Honorary fellow of Japanese Pulmonary Circulation and Pulmonary Hypertension Society
Implantable Cardioverter Defibrillator for Primary Prevention in Children With Arrhythmogenic Right Ventricular Cardiomyopathy: A Case Series. Cureus. 2025 Jan 10;17(1):e77253
Systematic Review of the Application of Pulmonary Hypertension Treatments in Ventricular Septal Defect, Pulmonary Atresia, and Major Aortopulmonary Collateral Arteries. J Clin Med. 2026 Jan 30;15(3):1087. doi: 10.3390/jcm15031087
Professor, Chonnam National University Medical School/ Hospital
Graduated from Chonnam University Medical School
Master of Medical Science from Graduate School of Chonnam National University
Ph.D. from Graduate School of Chonnam National University, Korea
Research fellow at Mayo Clinic, Rochester, MN, USA
President Elect, Korean Society of Pulmonary Hypertension
Director of Education & Training Committee, Korean Society of Cardiology
Director of Social Contribution Committee, Korean Society of Heart Failure
Director of Special Affairs Committee, Korean Society of Echocardiography
Auditor, Korean Vascular Society
CV Imaging
Cardiomyopathy and myo/pericarditis
Heart failure
Pulmonary hypertension/embolism
Valvular heart diseases
COVID-19 vaccination-related myocarditis: a Korean nationwide study. European Heart Journal 2023 (Corresponding Author, IF = 35.7)
COVID-19 Vaccination-Related Pericarditis: A Korean Nationwide Study. Mayo Clinic Proceedings 2024 (Corresponding Author, IF = 6.7)
Effusive-Constrictive Pericarditis After Pericardiocentesis: Incidence, Associated Findings, and Natural History. JACC CV Imaging 2018 (First Author, IF = 15.2) Published 355 papers (291 international, first or corresponding author: 83 papers)
Sungkyunkwan University School of Medicine (1998 ~ 2004)
Graduate school of Sungkyunkwan University, Master of Medical science (2008-2011)
Graduate school of Sungkyunkwan University, Ph. D. of Medical science (2012-2015)
Internship: Kangbuk Samsung Medical Center (2004.3 ~ 2005.2) Residency: Samsung Medical Center (2005.3 ~ 2009.2)
Public Health Service, Chungbook National University Hospital (2009.5 ~ 2012.4) Fellowship: Samsung Medical Center (2012.5 ~ 2014.2)
Instructor, Samsung medical center - Sungkyunkwan University School of Medicine (2014.3 ~ 2015.2)
Assistant professor, Samsung Medical Center (2015.3 ~ 2019.2) Associate professor, Samsung Medical Center (2019.3~ )
Diagnostic Value of FDG PET/CT in Surveillance after Curative Resection of Breast Cancer. Lee H, Choi JY, Park YH, Lee JE, Kim SW, Nam SJ, Cho YS.Cancers (Basel). 2023 May 7;15(9):2646. doi: 10.3390/cancers15092646.
Development and Validation of 18F-FDG PET/CT-Based Models for Predicting Successful Complete Cytoreduction During Primary Cytoreductive Surgery for Advanced Ovarian cancer. Kim J, Gil J, Kim SI, Hwangbo S, Noh JJ, Lee JW, Cheon GJ, Kim JW, Cho YS, Lee M.Clin Nucl Med. 2023 Feb 1;48(2):e51-e59. doi: 10.1097/RLU.0000000000004417. Epub 2022 Sep 30.PMID: 36607373
Genipin, an Inhibitor of UCP2 as a Promising New Anticancer Agent: A Review of the Literature. Cho YS.Int J Mol Sci. 2022 May 18;23(10):5637. doi: 10.3390/ijms23105637.PMID: 3562844
Usefulness of 99mTc-SESTAMIBI Scintigraphy in Persistent Hyperparathyroidism after Kidney Transplant. Shin M, Choi JY, Kim SW, Kim JH, Cho YS.Nucl Med Mol Imaging. 2021 Dec;55(6):285-292. doi: 10.1007/s13139-021-00722-6. Epub 2021 Oct 30.PMID: 34868377
COVID-19 Vaccination-Associated Lymphadenopathy on FDG PET/CT: Distinctive Features in Adenovirus-Vectored Vaccine. Shin M, Hyun CY, Choi YH, Choi JY, Lee KH, Cho YS. Clin Nucl Med. 2021 Jun 10. CV(Curriculum Vitae) 이력서 최종 수정일 : 2025년03월10일doi: 10.1097/RLU.0000000000003800. Online ahead of print.PMID: 34115709
Prognostic Significance of Metabolic Parameters by 18F-FDG PET/CT in Thymic Epithelial Tumors. Lee J, Cho YS, Kim J, Shim YM, Lee KH, Choi JY.Cancers (Basel). 2021 Feb 9;13(4):712. doi: 10.3390/cancers13040712.PMID: 33572388
Genipin enhances the antitumor effect of elesclomol in A549 lung cancer cells by blocking uncoupling protein-2 and stimulating reactive oxygen species production. Lee JH, Cho YS, Jung KH, Park JW, Lee KH.Oncol Lett. 2020 Dec;20(6):374. doi: 10.3892/ol.2020.12237. Epub 2020 Oct 21.PMID: 33154772
Serum uric acid in asymptomatic adults is weakly associated with carotid artery FDG uptake but not intima-media thickness. Cho YS, Bae JH, Moon SH, Hyun SH, Choi JY, Kim BT, Lee KH.J Nucl Cardiol. 2020 Oct;27(5):1537-1546. doi: 10.1007/s12350-018-1424-3. Epub 2018 Aug 28.PMID: 30155781
Molecular mechanism of (18)F-FDG uptake reduction induced by genipin in T47D cancer cell and role of uncoupling protein-2 in cancer cell glucose metabolism. Cho YS, Lee JH, Jung KH, Park JW, Moon SH, Choe YS, Lee KH.Nucl Med Biol. 2016 Oct;43(10):587-92. doi: 10.1016/j.nucmedbio.2016.06.001. Epub 2016 Jun 7.PMID: 27451963
Clinical Significance of Incidental 18F-FDG Uptake in the Pyriform Sinus Detected by PET/CT. Cho YS, Moon SH, Choi JY, Choe YS, Kim BT, Lee KH.Clin Nucl Med. 2016 Feb;41(2):e82-6. doi: .1097/RLU.0000000000000992.PMID: 26402129
Feb. 1999 Bachelor Degree, Yonsei University College of Medicine, Seoul, Korea
Aug. 2004 Master’s Degree of Medicine, Yonsei University College of Medicine, Seoul, Korea
Feb. 2007 Ph.D. Course of Medicine, Yonsei University College of Medicine, Seoul, Korea
2000-2004 Residency, Department of Radiology, Severance Hospital, Yonsei University College of Medicine
2004-2007 Clinical and Research Fellowship
2007-2009 Full-time lecturer
2009-2014 Assistant professor
2014-2020 Associate professor
2015-2016 Visiting scholar, University of Oxford Centre for Clinical Magnetic Resonance Research, Oxford, UK
2020- Professor, Department of Radiology, Severance Hospital, Yonsei University College of Medicine
Cardiac magnetic resonance/CT
Structural heart disease, Cardiomyopathy, Congenital heart disease
Tissue characterization using cardiac magnetic resonance imaging and response to cardiac resynchronization therapy. Europace Vol.27(4) : euaf043, 2025-04
Assessment of Device Neoendothelialization with Cardiac Computed Tomography Angiography After Transcatheter Closure of Atrial Septal Defect. Circulation-Cardiovascular Imaging 15(7): 523-533, 2022-07
The image quality and diagnostic accuracy of T1-mapping-based synthetic late gadolinium enhancement imaging: comparison with conventional late gadolinium enhancement imaging in real-life clinical situation. Journal of Cardiovascular Magnetic Resonance. 24(1):28
Comparison of Cardiac Computed Tomography with Transesophageal Echocardiography for Identifying Vegetation and Intracardiac Complications in Patients with Infective Endocarditis in the Era of 3-Dimensional Images. Circ Cardiovasc Imaging 11(3): e006986
Assessment of Mitral Paravalvular Leakage After Mitral Valve Replacement Using Cardiac Computed Tomography: Comparison With Surgical Findings. Circ Cardiovasc Imaging 9(6):e004153
Major in Bachelor of Arts in Doctor of Medicine (February 2009~Feburary 2015)
Internship Severance hospital, Yonsei University College of Medicine, Seoul, Korea (March 2015~February 2016)
Resident Division of internal medicine, Severance hospital, Yonsei University College of Medicine, Seoul, Korea (March 2016~February 2020)
Fellow Division of Cardiology, Severance Cardiovascular hospital, Yonsei University College of Medicine, Seoul, Korea (March 2020~February 2022)
Assistant professor Division of Cardiology, Keimyung University Dongsan Hospital (March 2022~Dec 2024)
Assistant professor Division of Cardiology, Yonsei University Severance Hospital (March 2025~)
Carney complex: Cardiac and extra-cardiac features (January 2020, European Heart Journal)
Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease (March 2020, ESC Heart Failure)
Cholesterol Efflux and Collateral Circulation in Chronic Total Coronary Occlusion: Effect‐Circ Study (May 2021, Journal of the American Heart Association)
The role of cardiac CT throughout the full cardiac cycle in diagnosing patent foramen ovale in patients with acute stroke (June 2021, European Radiology)
Prognostic Implications of Left Ventricular Global Longitudinal Strain in Patients With Surgically Treated Mitral Valve Disease and Preserved Ejection Fraction (January, 2022, FRONTIERS IN CARDIOVASCULAR MEDICINE)
Cancer Therapy-Related Cardiac Dysfunction in Patients Treated with a Combination of an Immune Checkpoint Inhibitor and Doxorubicin. (May 2022, Cancers)
Proteome-wide Characterization and Pathophysiology Correlation in Non-ischemic Cardiomyopathies (Aug 2024, Korean Circulation Journal)
Korean Society of Cardiology
Korean Society of Heart failure
Korean Society of echocardiography
Clinical study of cardio-oncology (2021)
GCP training (March 2022)
Apr 2023 - KAIRB Investigator supplementary education course
Mar 2025 – KAIRB Investigator supplementary education course
Mar.2007- Feb 2009 Postgraduate School, Seoul National University, Seoul, Korea(Ph.D. in Medical Science)
Mar.2002-Feb. 2004 Postgraduate School, Seoul National University, Seoul, Korea(Master of Medical Science)
Mar.1995 -Feb.1999 College of Medicine, Seoul National University, Seoul, Korea(M.D.)
Mar. 1993-Feb.1995 Premedical Course, College of Liberal Arts & ScienceSeoul National University, Seoul, Korea
Mar.1990- Feb.1993 Seoul Science High School, Seoul, Korea
Sep.2023-present Director of Pulmonary Hypertension & Venous Thrombosis Center, Asan Medical Center, Seoul, Korea
Sep.2021-present Professor in Cardiology Asan Medical Center, Ulsan college of medicine, Seoul, Korea
Mar.2020-present Director of Echocardiography Laboratory, Asan Medical Center, Seoul, Korea
Apr.2015- Aug.2021 Associate professor in Cardiology Asan Medical Center, Ulsan college of medicine, Seoul, Korea
Feb.2016-Feb.2018 Research fellow, Harvard medical school, Massachusetts General Hospital, Boston, USA
Mar.2010-Mar.2015 Assistant professor in Cardiology Asan Medical Center, Ulsan college of medicine, Seoul, Korea
Mar.2009-Feb.2010 Clinical Fellowship in echocardiography & cardiac imagingAsan Medical Center, Seoul, Korea
May.2007-Feb.2009 Clinical Fellowship in general cardiology, Seoul National University Hospital, Seoul, Korea
Apr.2004- Apr.2007 Public Health Doctor Ministry of Health & Welfare, Korea
Mar.2000-Feb.2004 Residency in Internal medicine Seoul National University Hospital, Seoul, Korea
Mar.1999-Feb.2000 Internship, Seoul National University Hospital, Seoul, Korea
Echocardiography
Cardiac CT imaging
Valvular heart disease
Hypertension
Pulmonary arterial hypertension
(2009.3-2013.2) M.D. College of Medicine, Gachon university
(2021.3-2024.8) PhD, College of Medicine, Gachon university
(2013.3-2018.2) Internship & Resident, Department of Internal Medicine, Gachon University Gil Medical Center
(2018.3-2020.2) Clinical fellow, Division of Rheumatology, Department of Internal Medicine, Gachon University Gil Medical Center
(2020.3-2021.2) Clinical fellow, Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital
(2021.3-2024.2) Clinical assistant professor, Division of Rheumatology, Department of Internal Medicine, Gachon University Gil Medical Center
(2024.3-) Assistant professor, Division of Rheumatology, Department of Internal Medicine, Gachon University Gil Medical Center
Chronic inflammatory disease/Systemic autoimmune disease
Yeo J, Kim JY, Kim MH, et al. Utility of the breath-holding test in patients with systemic sclerosis. Rheumatology (Oxford). 2022;61(10):4113-4118.
Yeo J, Park EA, Lee EB, et al. Angiographic characteristics of vasculopathy in patients with idiopathic inflammatory myopathies and systemic sclerosis. Sci Rep. 2022;12(1):9051.
Yeo J, Yoon SH, Kim JY, et al. Quantitative interstitial lung disease scores in idiopathic inflammatory myopathies: longitudinal changes and clinical implications. Rheumatology (Oxford). 2023;62(11):3690-3699.
Won Y, Yeo J, Jang Y, et al. Transition from parenteral treprostinil to selexipag aiming at hemodynamic targets in pulmonary arterial hypertension. Clin Hypertens. 2025;31(1):e5.
Yeo J, Kim MG K, Heo SY, et al. Dynamics of interleukin-23/interleukin-17 axis and type 1 regulatory T cells across disease stages in axial spondyloarthritis. Clin Exp Rheumatol. 2026.
Postdoctoral Fellowship-Molecular Medicine (2006) University of California, San Diego San Diego, California, USA
At United Therapeutics, Derek leads the ralinepag clinical development program including strategy and implementation at all stages. Derek leads and manages large, global, multicenter clinical studies, prepares late stage clinical study protocols and study reports, supports submission activities for marketing authorization, and provides due diligence support for new activities.
Ph.D.-Molecular Neuroscience (2001) Loyola University Chicago Chicago Illinois, USA
BS-Biology and Chemistry (cum laude with honors) (1995) University of Utah Salt Lake City Utah USA
2015-Current Associate Vice President, United Therapeutics Research Triangle Park, North Carolina, USA
2009-2015 Manager, Clinical Development Quintiles Transnational Morrisville, North Carolina, USA
2007-2009 Faculty, Department of Biological Sciences University of Washington Seattle, Washington, USA
Pulmonary hypertension (PH) clinical research is a rapidly evolving field focused on understanding heterogeneous causes of elevated pulmonary artery pressure, uncovering mechanisms of pulmonary vascular remodeling and right heart failure, and developing targeted, therapies to improve survival and quality of life.
McLaughlin V, Solum D, Lachant D, Ataya A, Barberà JA, Bohns-Meyer G, Chang S, Channick R, Church C, Feenstra J, Gaine S, Giannakoulas G, Jerjes-Sanchez C, Khanna D, Kim NH, Oudiz R, Preston IR, Sood N, Torres F, Vachiery JL, Pulido T, Cella D, Deng C, Escudero M, Lacasse V, Peterson L, Benza R, Humbert M (2026) Ralinepag for the Treatment of Pulmonary Arterial Hypertension: A Randomised, Double-blind, Placebo-controlled Phase 3 Study. Lancet. In Press
Barbera J, Jansa P, Klings E, Ristic A, Keogh A, Solum D, Rao Y, Grover R, Saib I, Sood N. (2024) Ralinepag Phase II open-label extension study in patients with pulmonary arterial hypertension. Adv Ther. https://doi.org/10.1007/s12325-023-02769-7.
Hopper RK, Ivy DD, Yung D, Mullen MP, Hanna BD, Kirkpatrick E, Hirsch R, Austin ED, Fineman J, Solum D, Deng CQ, Feinstein JA. (2020) Pharmacokinetics of oral treprostinil in children with pulmonary arterial hypertension. J Cardiovasc Pharmacol. Jul;76(1):94-100. doi: 10.1097/FJC.
Ivy, D, Feinstein, JA, Yung, D, Mullen MP, Kirkpatrick, E, Hirsch R, Austin, ED, Fineman J,Truong, U, Solum, D, Deng, CQ, Hopper, RK (2019) Oral Treprostinil in Transition or as Add-on Therapy in Pediatric Pulmonary Arterial Hypertension. Pulmonary Circulation. Pulmonary Circulation, 9(3) 1-8.